Form 8-K TG THERAPEUTICS, INC. For: May 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
TG Therapeutics (TGTX) PT Raised to $40 at Ladenburg Thalmann
May 2, 2024 6:34 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on TG Therapeutics (NASDAQ: TGTX) to $40.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "Strong BRIUMVI 1Q24 revenues with >25% Q/Q growth; TGTX increased BRIUMVI 2024 revenue guidance to $270-$290 million from $220-$260 million. TG... More



